Cordis makes a few exec changes

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Cordis, a subsidiary of Johnson & Johnson, has appointed three new senior-level executives.

Carl J. St. Bernard has been named vice president, U.S. sales and marketing; Paul I. Chang, MD, has been named vice president of worldwide clinical research and operations; and Ryan H. Saadi, MD, has been named vice president of health economics and reimbursement, according the Warren, N.J.-based company.

St. Bernard joins Cordis after serving as general manager of MRI at GE Healthcare, where he spent 12 years on the sales force. St. Bernard will become a member of the global management board at Cordis and also will chair the U.S. operating board.

Paul I. Chang, MD, who is succeeding Dennis Donohoe, MD,  who retired in August, will become a member of the research and development leadership team and will be responsible for clinical development strategy, clinical trial execution, and the program management office. Chang joined Johnson & Johnson pharmaceutical research and development in 2006 as therapeutic area head of cardiovascular and transitioned to head of Internal Medicine, R &D late last year, Cordis said. Prior to Johnson & Johnson, Chang was chief medical officer and vice president, regulatory affairs and clinical development at Tengion.

As vice president of Health Economics and Reimbursement, Saadi will play a role in Cordis’ growth, especially as the healthcare and medical device industry changes. Saadi joins Cordis from Genzyme, where he was vice president of global health outcomes and strategic pricing, supervising U.S. and European-based health economics and outcomes research, pricing and reimbursement teams, Cordis said. Prior to Genzyme, Saadi was senior director of oncology, bone and arthritis, global health outcomes and market access at Sanofi Aventis Pharmaceuticals.